20, November 2012

ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the...

Click here for more details

15, November 2012

ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatol...

Click here for more details

08, October 2012

Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun furt...

Click here for more details

07, September 2012

ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York - Tuesday 11 September 2012

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investmen...

Click here for more details

13, July 2012

ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012

ImmuPharma PLC (LSE: IMM) (“ImmuPharma” or the “Company”), the specialist discovery and development pharmaceutical company, has been voted "Best Medical Research and Development Company, Europe" at...

Click here for more details

03, July 2012

ImmuPharma PLC Appoints Cenkos Securities as Joint Broker

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immed...

Click here for more details

27, March 2012

PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2011.

...

Click here for more details

29, February 2012

ImmuPharma PLC Appoints Head of Investor Relations

ImmuPharma PLC (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations. 
 
...

Click here for more details